SCHEMBL9933464

SCHEMBL9933464

COC(=O)c1ccc(C#CCC[C@@H](NC(=O)OCc2ccc(OC)cc2)[C@H](O[Si](C)(C)C(C)(C)C)c2ccc(Cl)nc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.36
ALDH1A1 P00352 4/20 0.36
TSHR P16473 1/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ATM Q13315 1/20 0.35
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
PTPN6 P29350 1/20 0.33
PTPN11 Q06124 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33
NR1H4 Q96RI1 1/20 0.32
APLNR P35414 1/20 0.32
MAPT P10636 2/20 0.32
ACACB O00763 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21278203 0.92 NPC1 (0.38) CYP3A4ALDH1A1TSHRTP53MEN1
SCHEMBL16619518 0.92 NPC1 (0.38) CYP3A4ALDH1A1TSHRTP53MEN1
SCHEMBL21278564 0.90 CYP3A4 (0.33) CYP3A4ALDH1A1TSHRTP53ATM
SCHEMBL21278415 0.86 CYP3A4 (0.35) CYP3A4ALDH1A1TSHRTP53KMT2A
SCHEMBL9962995 0.86 ATM (0.39) ALDH1A1MEN1KMT2AATMNPC1
SCHEMBL16185906 0.82 ATM (0.42) CYP3A4ALDH1A1TSHRTP53ATM
SCHEMBL9933447 0.82 CHRNB2 (0.35) ALDH1A1TSHRKMT2APTPN11MAPT
SCHEMBL11964098 0.79 ATM (0.43) ALDH1A1KMT2AATM
SCHEMBL21278207 0.77 ATM (0.41) ALDH1A1TP53MEN1KMT2AATM
SCHEMBL16630235 0.77 ATM (0.41) ALDH1A1TP53MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604038-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-12-10 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-09-06 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CYP3A4 854/4885ALDH1A1 534/4885TSHR 331/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CYP3A4 854/4885ALDH1A1 534/4885TSHR 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.